BILIARY EXCRETION AND CLINICAL EFFICACY OF AT-2266
スポンサーリンク
概要
- 論文の詳細を見る
A new broad- spectrum synthetic antibacterial agent, ATAT-2266, was administered to 6 patients with postoperative biliary tract infection for preclinical and clinical studies.<BR>Peak concentrations in plasma and bile after oral administration of 200 mg of AT-2266 were 0.378-3.14μg/ml and 0.869-46.2μg/ml, respectively. The plasma concentration remained substantially unchanged within 4 hours after administration, whereas the biliary concentration increased with time and was 2.11-11.19 times as high as the plasma concentration at 3-4 hours.<BR>Preventionally, ATAT-2266 was effective in all 6 cases and no side effects were encountered. Twenty percent of <I>S. faecalis</I> (5 strains) were eradicated, whereas all of <I>E. cloacae</I> (1 strain), <I>E. aerogenes</I> (1 strain), <I>S. marcescens</I> (1 strain), <I>P. morganii</I> (1 strain) and <I>A. calcoaceticus</I> (1 strain) were eradicated.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.